Structure Therapeutics (GPCR) Interest Expenses (2022 - 2026)

Structure Therapeutics' Interest Expenses history runs 5 years deep, the most recent figure standing at $800000.0 for Q1 2026.

• On a quarterly basis, Interest Expenses rose 33.33% year-over-year to $800000.0 in Q1 2026; TTM through Mar 2026 was $2.6 million, a 73.33% increase from a year earlier, with the FY2025 full-year figure at $253.9 million, up 272.4% from the prior year.
• Interest Expenses steadied at $800000.0 in Q1 2026 per GPCR's latest filing, from $800000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $158.9 million in Q3 2023 and bottomed at $100000.0 in Q1 2022.
• The 5-year median for Interest Expenses is $800000.0 (2025), against an average of $39.0 million.
• Across the five-year window, Interest Expenses soared 158763.0% in 2023 and tumbled 99.45% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $100000.0 in 2022, then surged by 300.0% to $400000.0 in 2023, then changed by 0.0% to $400000.0 in 2024, then soared by 100.0% to $800000.0 in 2025, then changed by 0.0% to $800000.0 in 2026.
• Per Business Quant, the three latest GPCR Interest Expenses figures stand at $800000.0 (Q1 2026), $800000.0 (Q4 2025), and $7.9 million (Q3 2025).